Holen Sie sich die Stockscreener-App
1.58
2.47%
-0.04
Handel nachbörslich:
1.67
0.09
+5.70%
Schlusskurs vom Vortag:
$1.62
Offen:
$1.6
24-Stunden-Volumen:
292.84K
Relative Volume:
1.02
Marktkapitalisierung:
$105.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-56.85M
KGV:
-1.0135
EPS:
-1.559
Netto-Cashflow:
-
1W Leistung:
-7.06%
1M Leistung:
-16.84%
6M Leistung:
-23.30%
1J Leistung:
-64.57%
1-Tages-Spanne:
$1.57
$1.698
1-Wochen-Bereich:
$1.54
$1.815
52-Wochen-Spanne:
$0.873
$4.92
Fractyl Health Inc Stock (GUTS) Company Profile
Firmenname
Fractyl Health Inc
Sektor
Branche
Telefon
781-902-8800
Adresse
3 VAN DE GRAAFF DRIVE, BURLINGTON
Vergleichen Sie GUTS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
1.58 | 105.79M | 0 | -56.85M | 0 | -1.559 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-27 | Eingeleitet | BofA Securities | Buy |
| 2024-02-27 | Eingeleitet | Morgan Stanley | Overweight |
Fractyl Health Inc Aktie (GUTS) Neueste Nachrichten
Fractyl Health receives two new patents for duodenal resurfacing tech By Investing.com - Investing.com South Africa
Fractyl Health Obtains 2 US Patents for Duodenal Resurfacing - MarketScreener
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New - Bluefield Daily Telegraph
Fractyl Health Secures 2 Key Patents for Breakthrough Metabolic Disease Treatment | GUTS Stock News - Stock Titan
Bank of America Corp DE Sells 26,192 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Fractyl Health to Present New Preclinical Data from its - GlobeNewswire
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene ... - Eagle-Tribune
Fractyl Reveals Single-Dose Gene Therapy Data for Diabetes Treatment at ADA 2025 | GUTS Stock News - Stock Titan
Jane Street Group LLC Boosts Stake in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Nuveen Asset Management LLC Has $150,000 Stock Position in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Fractyl, Bariendo developing off-ramp for post-GLP-1 maintenance - BioWorld MedTech
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide - marketscreener.com
Fractyl Health and Bariendo Sign Letter of Intent to - GlobeNewswire
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide - Yahoo Finance
Northern Trust Corp Sells 9,467 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Fractyl Health, Inc. (NASDAQ:GUTS) Shares Sold by Citadel Advisors LLC - Defense World
Transcript : Fractyl Health, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 05 - MarketScreener
Fractyl Health submits first module of its CTA in Europe for RJVA-001 - TipRanks
Fractyl Health advances gene therapy for diabetes treatment By Investing.com - Investing.com South Africa
Fractyl Health advances gene therapy for diabetes treatment - Investing.com Australia
Fractyl Health Submits Clinical Trial Application in Europe - TipRanks
Fractyl Health Submits First Module of EU Trial Application for Gene Therapy RJVA-001 - marketscreener.com
Fractyl Health Unveils Promising Gene Therapy Data - TipRanks
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial ... - Eagle-Tribune
Fractyl Health Advances Rejuva® Gene Therapy Platform with - GlobeNewswire
Breakthrough One-Time Gene Therapy Could Replace Daily Diabetes Drugs, Heads to European Trials - Stock Titan
China On the March as U.S. Investors Plough Back in After Tariff Tension - The Globe and Mail
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 - The Manila Times
Fractyl Health Announces Promising Preclinical Data for RJVA-001, a Novel Gene Therapy for Type 2 Diabetes at ASGCT 2025 - Nasdaq
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data ... - Eagle-Tribune
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic - GlobeNewswire
Revolutionary One-Time GLP-1 Gene Therapy Achieves Powerful Diabetes Control with 5X Lower Side Effect Risk - Stock Titan
Prediction: Taiwan Semiconductor Stock Could Surge by 129% in the Next 5 Years - The Globe and Mail
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise - The Globe and Mail
Analysts and Institutions Continue to Bet Big on Alphabet - The Globe and Mail
16,400 Shares in Fractyl Health, Inc. (NASDAQ:GUTS) Bought by Raymond James Financial Inc. - Defense World
Fractyl signals accelerated enrollment for REMAIN-1 study while advancing Rejuva clinical milestones - MSN
Forge Biologics Inks AAV Development and cGMP Manufacturing Deal with Fractyl Health - Genetic Engineering and Biotechnology News
Fractyl Health Partners with Forge for Rejuva Gene Therapy Development - Contract Pharma
Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases - Business Wire
1 Super Stock Down 76% You'll Regret Not Buying on the Dip in 2025 - The Globe and Mail
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Fractyl Health Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Fractyl Health’s Q1 2025 shows rising R&D costs - Investing.com Nigeria
FRACTYL HEALTH, INC. SEC 10-Q Report - TradingView
Should You Buy Roku Stock Now With $500 and Hold for 10 Years? - The Globe and Mail
These High-Growth Stocks Were Down Over 50% This Year. Is It Time to Buy Them? - The Globe and Mail
Fractyl Health (GUTS) Expected to Announce Earnings on Tuesday - Defense World
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference - The Manila Times
Fractyl Health to Report First Quarter 2025 Financial - GlobeNewswire
Finanzdaten der Fractyl Health Inc-Aktie (GUTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fractyl Health Inc-Aktie (GUTS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barnes Kelly Ann | Director |
Mar 14 '25 |
Buy |
1.30 |
31,000 |
40,210 |
31,000 |
| SCHULMAN AMY W | Director |
Mar 13 '25 |
Buy |
1.17 |
8,550 |
9,964 |
8,550 |
| BRADLEY WILLIAM | Director |
Mar 13 '25 |
Buy |
1.26 |
16,129 |
20,358 |
16,129 |
| Conaway Samuel | Director |
Mar 13 '25 |
Buy |
1.17 |
8,550 |
9,964 |
8,550 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 31 '25 |
Option Exercise |
1.70 |
90,972 |
154,652 |
582,301 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 30 '25 |
Option Exercise |
1.70 |
20,948 |
35,612 |
512,277 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 31 '25 |
Sale |
1.82 |
90,972 |
165,205 |
491,329 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 30 '25 |
Sale |
1.95 |
20,948 |
40,798 |
491,329 |
| Caplan Jay David | President, Chief Product Off. |
Jan 31 '25 |
Option Exercise |
1.70 |
22,346 |
37,988 |
175,890 |
| Caplan Jay David | President, Chief Product Off. |
Jan 30 '25 |
Option Exercise |
1.70 |
21,472 |
36,502 |
175,016 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):